Table 1.
Patient characteristics.
| Characteristic | NDMM (n = 13) |
pPCL (n = 5) |
RRMM (n = 31) |
|
|---|---|---|---|---|
| Age, median (range) | 75 (31–86) | 65 (57–97) | 66 (46–77) | |
| Male sex, n (%) | 7 (54) | 2 (40) | 16 (52) | |
| M protein, n (%) | ||||
| IgG | 6 (50) | 2 (40) | 22 (71) | |
| IgA | 0 | 0 | 4 (13) | |
| FLC only | 6 (50) | 3 (60) | 5 (16) | |
| Unknown | 1 (8) | 0 | 0 | |
| ISS score, n (%) | ||||
| 1 | 2 (29) | 0 | n.a. | |
| 2 | 3 (43) | 1 (25) | ||
| 3 | 2 (29) | 3 (75) | ||
| Unknown | 6 (46) | 1 (20) | ||
| High risk cytogenetics a, n (%) | 1 (8) | 3 (75) | 6 (23) | |
| Unknown | 1 (8) | 1 (20) | 5 (16) | |
| Del (17p) | 1 (8) | 3 (75) | 4 (15) | |
| t (4;14) | 1 (8) | 1 (25) | 2 (8) | |
| t (14;16) | 0 | 0 | 0 | |
| Prior lines of therapy, median (range) | 0 | 0 | 3 (1–9) | |
| Prior autologous SCT, n (%) | ||||
| Single | n.a. | n.a. | 17 (61) | |
| Double | 2 (7) | |||
| Prior allogeneic SCT, n (%) | n.a. | n.a. | 2 (7) | |
| Lenalidomide, n (%) | ||||
| Exposed | n.a. | n.a. | 27 (87) | |
| Refractory b | 26 (84) | |||
| Pomalidomide, n (%) | ||||
| Exposed | n.a. | n.a. | 16 (52) | |
| Refractory b | 16 (52) | |||
| Bortezomib, n (%) | ||||
| Exposed | n.a. | n.a. | 27 (87) | |
| Refractory | 13 (42) | |||
| Carfilzomib, n (%) | ||||
| Exposed | n.a. | n.a. | 9 (29) | |
| Refractory | 7 (23) | |||
| Daratumumab, n (%) | ||||
| Exposed | n.a. | n.a. | 0 | |
| Refractory | 0 | |||
| IMiD and PI c | ||||
| Exposed | n.a. | n.a. | 27 (87) | |
| Refractory | 18 (58) | |||
a Based on the presence of del (17p), t (4;14), and/or t (14;16), some patients have more than one abnormality. b Refractory disease was defined as progressive disease during therapy, no response (less than PR), or progressive disease within 60 days of stopping treatment, according to the International Uniform Response Criteria for Multiple Myeloma. c Lenalidomide and/or pomalidomide plus bortezomib and/or carfilzomib. Abbreviations: HD, healthy donor; NDMM, newly diagnosed MM; RRMM, relapsed/refractory MM; DARA-R MM, daratumumab refractory MM; FLC, free light chains; ISS, International Staging System; SCT, stem cell transplantation; IMiD, immunomodulatory drug; PI, proteasome inhibitor; n.a., not applicable.